Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1 in Pulmonary Arterial Hypertension
NCT05224531Phase 2Completed
- Sponsor
- Cereno Scientific AB
- Start
- May 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bisantrene in pulmonary arterial hypertension (PAH), sponsored by Cereno Scientific AB. Started May 2022; status: completed.
02
Drugs
bisantrene
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05224531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05224531.